Rituximab-associated hypogammaglobulinemia in ANCA-associated vasculitis: Incidence and time course

Objective: Rituximab (RTX) is approved for remission induction and maintenance of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV). Observational studies demonstrate decline in immunoglobulin (IgG) in AAV post-RTX. The time course for the onset of hypogammaglobulinemia (Hypo-...

Descripción completa

Detalles Bibliográficos
Autores principales: Tariq, Anam, Akenroye, Ayobami, Azar, Antoine, Seo, Philip, Geetha, Duvuru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medical Research and Education Association 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176222/
https://www.ncbi.nlm.nih.gov/pubmed/35156624
http://dx.doi.org/10.5152/eujrheum.2022.20258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176222/
https://www.ncbi.nlm.nih.gov/pubmed/35156624
http://dx.doi.org/10.5152/eujrheum.2022.20258

Ejemplares similares